ArticlePediatric research2019
Erythropoietin serum levels, versus anaemia as risk factors for severe retinopathy of prematurity.
Article in Pediatric research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 31 citations in OpenAlex.
- Trial
- Effect of early prophylactic low-dose recombinant human erythropoietin on retinopathy of prematurity in very preterm infants.Journal of translational medicine · 2020Trial
- Evaluation of point-of-care hemoglobin testing vs. central laboratory measurements in neonates: a prospective study in neonatal intensive care unit.Frontiers in pediatrics · 2026Article
- Anemia and retinopathy of prematurity: A narrative review.Pediatric investigation · 2025Review
- Phlebotomy-induced anemia reduces oxygen-induced retinopathy severity and dampens retinal developmental transcriptomic pathways in rats.Pediatric research · 2025Article
- Red blood cell parameters as biomarkers of retinopathy of prematurity in preterm infants born before 30 weeks of gestation.Scientific reports · 2025Article
- Pathophysiology of Retinopathy of Prematurity.Annual review of vision science · 2023Review
- Retinopathy of prematurity protection conferred by uteroplacental insufficiency through erythropoietin signaling in an experimental Murine Model.Pediatric research · 2023Article
- Genetic Modulation of the Erythrocyte Phenotype Associated with Retinopathy of Prematurity-A Multicenter Portuguese Cohort Study.International journal of molecular sciences · 2023Article
- Systemic Cytokines in Retinopathy of Prematurity.Journal of personalized medicine · 2023Review
- Thrombocytopenia as Type 1 ROP Biomarker: A Longitudinal Study.Journal of personalized medicine · 2021Article
- Haemoglobin Levels in Early Life among Infants with and without Retinopathy of Prematurity.International journal of environmental research and public health · 2021Article
- Severe retinopathy of prematurity is associated with early post-natal low platelet count.Scientific reports · 2021Article
- Incidence and Risk Factors Associated with Retinopathy of Prematurity in Peru.Clinical ophthalmology (Auckland, N.Z.) · 2021Article
- Signaling Through the Erythropoietin Receptor Affects Angiogenesis in Retinovascular Disease.Investigative ophthalmology & visual science · 2020Article
- Current evidence and outcomes for retinopathy of prematurity prevention: insight into novel maternal and placental contributions.Exploration of medicine · 2020Article
- Does First Blood Draw Matter in Retinopathy of Prematurity: A Comparative Analysis of Inflammation and Hypoxia-Related Parameters.Romanian journal of ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundPreterm infants with anaemia are treated with recombinant human erythropoietin (rhEPO). It is debated whether rhEPO treatment is a risk factor for retinopathy of prematurity (ROP). We evaluated longitudinal EPO and haemoglobin levels, blood transfusions and neonatal morbidities as risk factors for severe ROP.
methodThis prospective study included 78 Swedish infants, born <28 weeks gestational age (GA), screened for ROP. We tested serum EPO levels on postnatal days 1, 7, 14 and 28 and at postmenstrual ages 32, 36 and 40 weeks. Haemoglobin levels and blood transfusions were recorded during postnatal weeks 1-4. Anaemia was defined as haemoglobin ≤110 g/L.
resultsDuring postnatal week 1, infants with severe ROP requiring treatment (28%) more frequently developed anaemia (42.9% versus 8.0%, P = 0.003) and had higher mean EPO levels (postnatal day 7: 14.2 versus 10.8 mIU/mL, P = 0.003) compared to infants with no or less severe ROP not requiring treatment. In multivariable analyses, GA and anaemia during week 1 remained significant risk factors, but elevated EPO level postnatal day 7 was no longer significant.
conclusionsAmong infants born <28 weeks GA, anaemia during week 1 was a significant risk factor for severe ROP requiring treatment but not elevated EPO levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.